Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
Accolade, Inc. (ACCD) delivers technology-powered healthcare solutions that combine virtual care with expert clinical navigation. This news hub provides investors and industry professionals with essential updates on the company’s strategic initiatives and market position.
Track official press releases, earnings announcements, and operational developments through our curated collection. Find timely information on healthcare partnerships, service expansions, and technology innovations that shape Accolade’s role in personalized care solutions.
Our repository includes updates across key business areas: financial results, leadership changes, clinical program enhancements, and regulatory milestones. Each entry is sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for streamlined access to ACCD’s evolving story in healthcare technology. Monitor how the company’s unique blend of digital tools and clinical expertise continues to redefine employer-sponsored and individual healthcare navigation.
Accolade (NASDAQ: ACCD) announced financial results for fiscal Q2 2025 ended August 31, 2024. Revenue increased 10% to $106.4 million, while net loss improved 27% to $23.9 million. Non-GAAP Adjusted EBITDA loss narrowed 68% to $2.8 million, and Adjusted Gross Margin expanded to 47.3%.
CEO Rajeev Singh stated that Accolade is positioned to deliver its first full year of Adjusted EBITDA profitability and positive cash flow. The company focuses on solving the Physician Gap through a physician-led advocacy approach. CFO Steve Barnes highlighted Accolade's execution in delivering profitable growth, with the net cash position improving by over $20 million compared to convertible debt in the past year.
Accolade, Inc. (NASDAQ: ACCD) has announced the release date for its fiscal second quarter 2025 financial results. The company will disclose the results on Tuesday, October 8, 2024, before market open. Following the release, Accolade will host a conference call at 8:00 a.m. E.T. to review the results.
Interested parties can participate in the conference call via telephone by pre-registering through a provided link. Upon registration, participants will receive dial-in information and a unique PIN. Alternatively, a live audio webcast of the call will be accessible online at the company's investor relations website. For those unable to attend live, a replay of the call will be available for one year via webcast on the same website.
Accolade (NASDAQ: ACCD) has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for Thursday, September 5 at 9:15 am ET in New York. Investors and interested parties can access a live webcast of the presentation through Accolade's investor relations website at ir.accolade.com. For those unable to attend or watch live, a replay of the presentation will be available on the same platform for 90 days following the event. This conference provides Accolade with an opportunity to showcase its healthcare technology solutions to a global audience of investors and industry professionals.
Celeste Health Solutions, a new healthcare company, is entering the market with an innovative approach to simplify healthcare access for employees and ease the burden for employers. The company integrates health navigation, personalized engagement, whole-person virtual care, point solutions, care management, and benefits support into a single, comprehensive product.
Key features of Celeste include:
- Smart care plans for each plan member
- An intuitive app for accessing all benefits
- Direct communication with Care Advocates
- The Innovations Hub, a curated portfolio of point solutions
- Consolidated contracting, billing, and reporting for employers
Celeste is partnering with Accolade (ACCD) to enhance personalization of health management services, combining virtual care options, expert medical opinions, clinical integration, and seamless navigation.
Accolade (NASDAQ: ACCD) has announced its participation in the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase in Boston. The presentation is scheduled for Wednesday, August 14 at 12:00 pm ET. Investors and interested parties can access a live webcast of the presentation through the company's investor relations website at ir.accolade.com. For those unable to attend or watch live, a replay of the presentation will be available on the same website for 90 days following the event.
This conference provides Accolade with an opportunity to showcase its growth strategies and recent developments to a wide audience of investors and industry professionals. The company's participation in such a prominent event suggests confidence in its business model and future prospects.
Accolade (NASDAQ: ACCD) announced its fiscal first-quarter 2025 results, highlighting significant improvements. The company reported a revenue increase of 18% year-over-year, reaching $110.5 million. Net loss improved by 28%, down to $27.6 million from $38.4 million in the same period last year. Adjusted EBITDA saw a substantial improvement of 73%, landing at negative $3.3 million compared to negative $12.6 million. Adjusted gross profit also rose by 30%, totaling $52.8 million, with an adjusted gross margin of 47.8%, up from 43.5%.
CEO Rajeev Singh emphasized Accolade's continued focus on healthcare accessibility and outcomes through their physician-led advocacy approach. CFO Steve Barnes highlighted the company's commitment to achieving profitable growth and positive Adjusted EBITDA within the year.
Accolade (NASDAQ: ACCD) announced the release date for its fiscal first quarter 2025 financial results. The report will be available on June 27, 2024, after the market closes. A conference call to review these results is scheduled for the same day at 4:30 p.m. ET. Interested parties must pre-register for the call, which will be accessible via telephone and a live audio webcast on Accolade's investor relations website. A replay of the call will be available for one year.
Accolade (NASDAQ: ACCD) has announced its participation in the William Blair Growth Stock Conference in Chicago. The company will present on June 4, 2024, at 2:00 pm CT. A webcast and a 90-day replay will be available on their investor relations website.
Accolade (Nasdaq: ACCD) has announced a partnership with Noom to enhance its Trusted Partner Ecosystem. This collaboration offers a comprehensive solution for weight loss and metabolic health, integrating Noom's coaching with Accolade's primary care physicians. Noom Med, part of this partnership, focuses on obesity management, including GLP-1 medications and other anti-obesity drugs. Noom's approach combines psychology, science, and personalized support, achieving a 25% employee adoption rate and 42% of users maintaining weight loss for two years. This partnership aims to reduce obesity-related healthcare costs and improve outcomes through evidence-based care and advanced primary care support.
FAQ
What is the current stock price of Accolade (ACCD)?
What is the market cap of Accolade (ACCD)?
